Peptide record

TPDB00615

Magainin 2 Magainin II Antibacterial Anticancer Antifungal Antioxidant Antiparasitic Antiviral Cell-penetrating Peptides Hemolysis Toxicity standard
23 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB00615
Magainin 2 Magainin II
Antibacterial Anticancer Antifungal Antioxidant Antiparasitic Antiviral Cell-penetrating Peptides Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides Delivery and barrier-penetrating peptides Functional / health-promoting peptides
AntiBP3 dbAMP DRAMP Peptipedia ACP740 _ACP240 AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF AFP-GFuse Antifungipept CAFPdb dbAMP 3.0 i2APP AI4AVP DRAVP 2.0 CPPsite3.0 APD_complete HemoPI Hemolytic2 PD_Hemolysis ToxinPred 3.0
standard
No
A 23-aa standard-residue multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Sequence
GIGKFLHSAKKFGKAFVGEIMNS
Physicochemical Analysis

Sequence-only estimates for a linear peptide with free termini, not experimentally measured molecular properties. Mass and formula exclude cyclization and disulfide formation. The optical estimates assume paired cysteines, 280 nm, 1 g/L and a 1 cm path. The N-end rule estimate is not a measured plasma half-life.

C114H180N30O29S1
RDCQPTWY
GK
2466.93
10.55
5
1
10
+3
0.42
0.083
72.17
Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour
0
0.00
3
Residue Composition
number
2
A
0
R
1
N
0
D
0
C
1
E
0
Q
4
G
1
H
2
I
1
L
4
K
1
M
3
F
0
P
2
S
0
T
0
W
0
Y
1
V
Amino Acid Distribution
A: 2 R: 0 N: 1 D: 0 C: 0 E: 1 Q: 0 G: 4 H: 1 I: 2 L: 1 K: 4 M: 1 F: 3 P: 0 S: 2 T: 0 W: 0 Y: 0 V: 1
Chemical Descriptors
23 reviewed residue count
C114H180N30O29S1 sequence-only estimate (linear, free termini)
2466.93 sequence-only estimate (linear, free termini)
10.55 sequence-only estimate (linear, free termini)
+3 sequence-only estimate (linear, free termini)
0.42 sequence-only estimate (linear, free termini)
0.083 sequence-only estimate (linear, free termini)
Free Activity
L Activity
Cationic Activity
Linear Activity
Linear Activity
Free Activity
Antimicrobial Activity
Xenopus laevis Activity
N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CS)C(=O)N[C@@H](Cc1[nH]cnc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)O Activity
Evidence Records 69 records
Evidence 1 Activity

Activity

MIC
Antibacterial
5 µg/mL

Target

Escherichia coli D31

Source & Reference

dbAMP DRAMP

Other

Source Activity Label Source Definition
Antibacterial
dbAMP classified as Antibacterial under the Anti-bacterial function class. DRAMP antibacterial activity supported by MIC records against bacterial target organisms.
Active against E. coli D31 (MIC 5 ug/ml), K. pneumoniae, P. putida, S. epidermidis (MIC 10 ug/ml), C. freundii (MIC 30 ug/ml), E.
Evidence 2 Activity

Activity

MIC
Antibacterial
10 µg/mL

Target

Staphylococcus epidermidis

Source & Reference

dbAMP DRAMP

Other

Active against E. coli D31 (MIC 5 ug/ml), K. pneumoniae, P. putida, S. epidermidis (MIC 10 ug/ml), C. freundii (MIC 30 ug/ml), E. cloacae, E. coli, S. aureus (MIC 50 ug/ml), C. albicans (
Evidence 3 Activity

Activity

MIC
Antibacterial
30 µg/mL

Target

Citrobacter freundii

Source & Reference

dbAMP DRAMP

Other

ainst E. coli D31 (MIC 5 ug/ml), K. pneumoniae, P. putida, S. epidermidis (MIC 10 ug/ml), C. freundii (MIC 30 ug/ml), E. cloacae, E. coli, S. aureus (MIC 50 ug/ml), C. albicans (MIC 80 ug/ml), P. aeruginosa
Evidence 4 Activity

Activity

MIC
Antibacterial
50 µg/mL

Target

Staphylococcus aureus

Source & Reference

dbAMP DRAMP

Other

. putida, S. epidermidis (MIC 10 ug/ml), C. freundii (MIC 30 ug/ml), E. cloacae, E. coli, S. aureus (MIC 50 ug/ml), C. albicans (MIC 80 ug/ml), P. aeruginosa, and S. marcescens (MIC 100 ug/ml). Also S. py
Evidence 5 Activity

Activity

MIC
Antibacterial
80 µg/mL

Target

Candida albicans

Source & Reference

dbAMP DRAMP

Other

MIC 10 ug/ml), C. freundii (MIC 30 ug/ml), E. cloacae, E. coli, S. aureus (MIC 50 ug/ml), C. albicans (MIC 80 ug/ml), P. aeruginosa, and S. marcescens (MIC 100 ug/ml). Also S. pyogenes, and S. cerevisiae. A
Evidence 6 Activity

Activity

MIC
Antibacterial
100 µg/mL

Target

S. marcescens

Source & Reference

dbAMP DRAMP

Other

loacae, E. coli, S. aureus (MIC 50 ug/ml), C. albicans (MIC 80 ug/ml), P. aeruginosa, and S. marcescens (MIC 100 ug/ml). Also S. pyogenes, and S. cerevisiae. Active against fungi C.albicans 315 or B311 (MIC >5
Evidence 7 Activity

Activity

MIC
Antibacterial
>500 µg/mL

Target

C.albicans 315 or B311

Source & Reference

dbAMP DRAMP

Other

S. marcescens (MIC 100 ug/ml). Also S. pyogenes, and S. cerevisiae. Active against fungi C.albicans 315 or B311 (MIC >500 ug/ml), C.glabrata 359 (MIC >500 ug/ml), C.krusei 355 (MIC >500 ug/ml), C.neoformans 316 (MIC >5
Evidence 8 Activity

Activity

MIC
Antibacterial
>500 µg/mL

Target

C.glabrata 359

Source & Reference

dbAMP DRAMP

Other

yogenes, and S. cerevisiae. Active against fungi C.albicans 315 or B311 (MIC >500 ug/ml), C.glabrata 359 (MIC >500 ug/ml), C.krusei 355 (MIC >500 ug/ml), C.neoformans 316 (MIC >500 ug/ml), and A.fumigatus X 8072
Evidence 9 Activity

Activity

MIC
Antibacterial
>500 µg/mL

Target

C.krusei 355

Source & Reference

dbAMP DRAMP

Other

e against fungi C.albicans 315 or B311 (MIC >500 ug/ml), C.glabrata 359 (MIC >500 ug/ml), C.krusei 355 (MIC >500 ug/ml), C.neoformans 316 (MIC >500 ug/ml), and A.fumigatus X 807219 (MIC>500 ug/ml) ( van't Hof
Evidence 10 Activity

Activity

MIC
Antibacterial
>500 µg/mL

Target

C.neoformans 316

Source & Reference

dbAMP DRAMP

Other

or B311 (MIC >500 ug/ml), C.glabrata 359 (MIC >500 ug/ml), C.krusei 355 (MIC >500 ug/ml), C.neoformans 316 (MIC >500 ug/ml), and A.fumigatus X 807219 (MIC>500 ug/ml) ( van't Hof et al., 2000 ). Also active against
Evidence 11 Activity

Activity

MIC
Antibacterial
>500 µg/mL

Target

A.fumigatus X 807219

Source & Reference

dbAMP DRAMP

Other

9 (MIC >500 ug/ml), C.krusei 355 (MIC >500 ug/ml), C.neoformans 316 (MIC >500 ug/ml), and A.fumigatus X 807219 (MIC>500 ug/ml) ( van't Hof et al., 2000 ). Also active against P. falciparum (IC50 ~100 uM) (see ref AP4
Evidence 12 Activity

Activity

IC50
IC50 = >60 µM
Anticancer
>60 µM

Target

Pancreatic Cancer
HeLa
Pancreatic

Assay & Model

WST-1 assay
Not Available

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2011

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation. dbAMP 3.0 classified as Anticancer under the disease-associated peptide function classes.
Evidence 13 Activity

Activity

MIC
Antifungal
5 µg/mL

Target

Escherichia coli D31

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Source Activity Label Source Definition
Antifungal
dbAMP classified under the Anti-fungal function class. DRAMP antifungal activity supported by activity records against fungal target organisms.
Active against E. coli D31 (MIC 5 ug/ml), K. pneumoniae, P. putida, S. epidermidis (MIC 10 ug/ml), C. freundii (MIC 30 ug/ml), E.
Evidence 14 Activity

Activity

MIC
Antifungal
10 µg/mL

Target

Staphylococcus epidermidis

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Active against E. coli D31 (MIC 5 ug/ml), K. pneumoniae, P. putida, S. epidermidis (MIC 10 ug/ml), C. freundii (MIC 30 ug/ml), E. cloacae, E. coli, S. aureus (MIC 50 ug/ml), C. albicans (
Evidence 15 Activity

Activity

MIC
Antifungal
30 µg/mL

Target

Citrobacter freundii

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

ainst E. coli D31 (MIC 5 ug/ml), K. pneumoniae, P. putida, S. epidermidis (MIC 10 ug/ml), C. freundii (MIC 30 ug/ml), E. cloacae, E. coli, S. aureus (MIC 50 ug/ml), C. albicans (MIC 80 ug/ml), P. aeruginosa
Evidence 16 Activity

Activity

MIC
Antifungal
50 µg/mL

Target

Staphylococcus aureus

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

. putida, S. epidermidis (MIC 10 ug/ml), C. freundii (MIC 30 ug/ml), E. cloacae, E. coli, S. aureus (MIC 50 ug/ml), C. albicans (MIC 80 ug/ml), P. aeruginosa, and S. marcescens (MIC 100 ug/ml). Also S. py
Evidence 17 Activity

Activity

MIC
Antifungal
80 µg/mL

Target

Candida albicans

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

MIC 10 ug/ml), C. freundii (MIC 30 ug/ml), E. cloacae, E. coli, S. aureus (MIC 50 ug/ml), C. albicans (MIC 80 ug/ml), P. aeruginosa, and S. marcescens (MIC 100 ug/ml). Also S. pyogenes, and S. cerevisiae. A
Evidence 18 Activity

Activity

MIC
Antifungal
100 µg/mL

Target

S. marcescens

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

loacae, E. coli, S. aureus (MIC 50 ug/ml), C. albicans (MIC 80 ug/ml), P. aeruginosa, and S. marcescens (MIC 100 ug/ml). Also S. pyogenes, and S. cerevisiae. Active against fungi C.albicans 315 or B311 (MIC >5
Evidence 19 Activity

Activity

MIC
Antifungal
>500 µg/mL

Target

C.albicans 315 or B311

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

S. marcescens (MIC 100 ug/ml). Also S. pyogenes, and S. cerevisiae. Active against fungi C.albicans 315 or B311 (MIC >500 ug/ml), C.glabrata 359 (MIC >500 ug/ml), C.krusei 355 (MIC >500 ug/ml), C.neoformans 316 (MIC >5
Evidence 20 Activity

Activity

MIC
Antifungal
>500 µg/mL

Target

C.glabrata 359

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

yogenes, and S. cerevisiae. Active against fungi C.albicans 315 or B311 (MIC >500 ug/ml), C.glabrata 359 (MIC >500 ug/ml), C.krusei 355 (MIC >500 ug/ml), C.neoformans 316 (MIC >500 ug/ml), and A.fumigatus X 8072
Evidence 21 Activity

Activity

MIC
Antifungal
>500 µg/mL

Target

C.krusei 355

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

e against fungi C.albicans 315 or B311 (MIC >500 ug/ml), C.glabrata 359 (MIC >500 ug/ml), C.krusei 355 (MIC >500 ug/ml), C.neoformans 316 (MIC >500 ug/ml), and A.fumigatus X 807219 (MIC>500 ug/ml) ( van't Hof
Evidence 22 Activity

Activity

MIC
Antifungal
>500 µg/mL

Target

C.neoformans 316

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

or B311 (MIC >500 ug/ml), C.glabrata 359 (MIC >500 ug/ml), C.krusei 355 (MIC >500 ug/ml), C.neoformans 316 (MIC >500 ug/ml), and A.fumigatus X 807219 (MIC>500 ug/ml) ( van't Hof et al., 2000 ). Also active against
Evidence 23 Activity

Activity

MIC
Antifungal
>500 µg/mL

Target

A.fumigatus X 807219

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

9 (MIC >500 ug/ml), C.krusei 355 (MIC >500 ug/ml), C.neoformans 316 (MIC >500 ug/ml), and A.fumigatus X 807219 (MIC>500 ug/ml) ( van't Hof et al., 2000 ). Also active against P. falciparum (IC50 ~100 uM) (see ref AP4
Evidence 24 Activity

Activity

MIC
Antiparasitic
5 µg/mL

Target

Escherichia coli D31

Source & Reference

dbAMP 3.0 DRAMP

Other

Source Activity Label Source Definition
Antiparasitic
DRAMP antiparasitic activity supported by activity records against parasitic targets. dbAMP 3.0 classified under the Anti-parasitic function class.
Active against E. coli D31 (MIC 5 ug/ml), K. pneumoniae, P. putida, S. epidermidis (MIC 10 ug/ml), C. freundii (MIC 30 ug/ml), E.
Evidence 25 Activity

Activity

MIC
Antiparasitic
10 µg/mL

Target

Staphylococcus epidermidis

Source & Reference

dbAMP 3.0 DRAMP

Other

Active against E. coli D31 (MIC 5 ug/ml), K. pneumoniae, P. putida, S. epidermidis (MIC 10 ug/ml), C. freundii (MIC 30 ug/ml), E. cloacae, E. coli, S. aureus (MIC 50 ug/ml), C. albicans (
Evidence 26 Activity

Activity

MIC
Antiparasitic
30 µg/mL

Target

Citrobacter freundii

Source & Reference

dbAMP 3.0 DRAMP

Other

ainst E. coli D31 (MIC 5 ug/ml), K. pneumoniae, P. putida, S. epidermidis (MIC 10 ug/ml), C. freundii (MIC 30 ug/ml), E. cloacae, E. coli, S. aureus (MIC 50 ug/ml), C. albicans (MIC 80 ug/ml), P. aeruginosa
Evidence 27 Activity

Activity

MIC
Antiparasitic
50 µg/mL

Target

Staphylococcus aureus

Source & Reference

dbAMP 3.0 DRAMP

Other

. putida, S. epidermidis (MIC 10 ug/ml), C. freundii (MIC 30 ug/ml), E. cloacae, E. coli, S. aureus (MIC 50 ug/ml), C. albicans (MIC 80 ug/ml), P. aeruginosa, and S. marcescens (MIC 100 ug/ml). Also S. py
Evidence 28 Activity

Activity

MIC
Antiparasitic
80 µg/mL

Target

Candida albicans

Source & Reference

dbAMP 3.0 DRAMP

Other

MIC 10 ug/ml), C. freundii (MIC 30 ug/ml), E. cloacae, E. coli, S. aureus (MIC 50 ug/ml), C. albicans (MIC 80 ug/ml), P. aeruginosa, and S. marcescens (MIC 100 ug/ml). Also S. pyogenes, and S. cerevisiae. A
Evidence 29 Activity

Activity

MIC
Antiparasitic
100 µg/mL

Target

S. marcescens

Source & Reference

dbAMP 3.0 DRAMP

Other

loacae, E. coli, S. aureus (MIC 50 ug/ml), C. albicans (MIC 80 ug/ml), P. aeruginosa, and S. marcescens (MIC 100 ug/ml). Also S. pyogenes, and S. cerevisiae. Active against fungi C.albicans 315 or B311 (MIC >5
Evidence 30 Activity

Activity

MIC
Antiparasitic
>500 µg/mL

Target

C.albicans 315 or B311

Source & Reference

dbAMP 3.0 DRAMP

Other

S. marcescens (MIC 100 ug/ml). Also S. pyogenes, and S. cerevisiae. Active against fungi C.albicans 315 or B311 (MIC >500 ug/ml), C.glabrata 359 (MIC >500 ug/ml), C.krusei 355 (MIC >500 ug/ml), C.neoformans 316 (MIC >5
Evidence 31 Activity

Activity

MIC
Antiparasitic
>500 µg/mL

Target

C.glabrata 359

Source & Reference

dbAMP 3.0 DRAMP

Other

yogenes, and S. cerevisiae. Active against fungi C.albicans 315 or B311 (MIC >500 ug/ml), C.glabrata 359 (MIC >500 ug/ml), C.krusei 355 (MIC >500 ug/ml), C.neoformans 316 (MIC >500 ug/ml), and A.fumigatus X 8072
Evidence 32 Activity

Activity

MIC
Antiparasitic
>500 µg/mL

Target

C.krusei 355

Source & Reference

dbAMP 3.0 DRAMP

Other

e against fungi C.albicans 315 or B311 (MIC >500 ug/ml), C.glabrata 359 (MIC >500 ug/ml), C.krusei 355 (MIC >500 ug/ml), C.neoformans 316 (MIC >500 ug/ml), and A.fumigatus X 807219 (MIC>500 ug/ml) ( van't Hof
Evidence 33 Activity

Activity

MIC
Antiparasitic
>500 µg/mL

Target

C.neoformans 316

Source & Reference

dbAMP 3.0 DRAMP

Other

or B311 (MIC >500 ug/ml), C.glabrata 359 (MIC >500 ug/ml), C.krusei 355 (MIC >500 ug/ml), C.neoformans 316 (MIC >500 ug/ml), and A.fumigatus X 807219 (MIC>500 ug/ml) ( van't Hof et al., 2000 ). Also active against
Evidence 34 Activity

Activity

MIC
Antiparasitic
>500 µg/mL

Target

A.fumigatus X 807219

Source & Reference

dbAMP 3.0 DRAMP

Other

9 (MIC >500 ug/ml), C.krusei 355 (MIC >500 ug/ml), C.neoformans 316 (MIC >500 ug/ml), and A.fumigatus X 807219 (MIC>500 ug/ml) ( van't Hof et al., 2000 ). Also active against P. falciparum (IC50 ~100 uM) (see ref AP4
Evidence 35 Activity

Activity

MIC
Antiviral
5 µg/mL

Target

Escherichia coli D31

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

Source Activity Label Source Definition
Antiviral
DRAMP antiviral activity supported by activity records against viral targets. dbAMP 3.0 classified under the Anti-viral function class.
Active against E. coli D31 (MIC 5 ug/ml), K. pneumoniae, P. putida, S. epidermidis (MIC 10 ug/ml), C. freundii (MIC 30 ug/ml), E.
Evidence 36 Activity

Activity

MIC
Antiviral
10 µg/mL

Target

Staphylococcus epidermidis

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

Active against E. coli D31 (MIC 5 ug/ml), K. pneumoniae, P. putida, S. epidermidis (MIC 10 ug/ml), C. freundii (MIC 30 ug/ml), E. cloacae, E. coli, S. aureus (MIC 50 ug/ml), C. albicans (
Evidence 37 Activity

Activity

MIC
Antiviral
30 µg/mL

Target

Citrobacter freundii

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

ainst E. coli D31 (MIC 5 ug/ml), K. pneumoniae, P. putida, S. epidermidis (MIC 10 ug/ml), C. freundii (MIC 30 ug/ml), E. cloacae, E. coli, S. aureus (MIC 50 ug/ml), C. albicans (MIC 80 ug/ml), P. aeruginosa
Evidence 38 Activity

Activity

MIC
Antiviral
50 µg/mL

Target

Staphylococcus aureus

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

. putida, S. epidermidis (MIC 10 ug/ml), C. freundii (MIC 30 ug/ml), E. cloacae, E. coli, S. aureus (MIC 50 ug/ml), C. albicans (MIC 80 ug/ml), P. aeruginosa, and S. marcescens (MIC 100 ug/ml). Also S. py
Evidence 39 Activity

Activity

MIC
Antiviral
80 µg/mL

Target

Candida albicans

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

MIC 10 ug/ml), C. freundii (MIC 30 ug/ml), E. cloacae, E. coli, S. aureus (MIC 50 ug/ml), C. albicans (MIC 80 ug/ml), P. aeruginosa, and S. marcescens (MIC 100 ug/ml). Also S. pyogenes, and S. cerevisiae. A
Evidence 40 Activity

Activity

MIC
Antiviral
100 µg/mL

Target

S. marcescens

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

loacae, E. coli, S. aureus (MIC 50 ug/ml), C. albicans (MIC 80 ug/ml), P. aeruginosa, and S. marcescens (MIC 100 ug/ml). Also S. pyogenes, and S. cerevisiae. Active against fungi C.albicans 315 or B311 (MIC >5
Evidence 41 Activity

Activity

MIC
Antiviral
>500 µg/mL

Target

C.albicans 315 or B311

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

S. marcescens (MIC 100 ug/ml). Also S. pyogenes, and S. cerevisiae. Active against fungi C.albicans 315 or B311 (MIC >500 ug/ml), C.glabrata 359 (MIC >500 ug/ml), C.krusei 355 (MIC >500 ug/ml), C.neoformans 316 (MIC >5
Evidence 42 Activity

Activity

MIC
Antiviral
>500 µg/mL

Target

C.glabrata 359

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

yogenes, and S. cerevisiae. Active against fungi C.albicans 315 or B311 (MIC >500 ug/ml), C.glabrata 359 (MIC >500 ug/ml), C.krusei 355 (MIC >500 ug/ml), C.neoformans 316 (MIC >500 ug/ml), and A.fumigatus X 8072
Evidence 43 Activity

Activity

MIC
Antiviral
>500 µg/mL

Target

C.krusei 355

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

e against fungi C.albicans 315 or B311 (MIC >500 ug/ml), C.glabrata 359 (MIC >500 ug/ml), C.krusei 355 (MIC >500 ug/ml), C.neoformans 316 (MIC >500 ug/ml), and A.fumigatus X 807219 (MIC>500 ug/ml) ( van't Hof
Evidence 44 Activity

Activity

MIC
Antiviral
>500 µg/mL

Target

C.neoformans 316

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

or B311 (MIC >500 ug/ml), C.glabrata 359 (MIC >500 ug/ml), C.krusei 355 (MIC >500 ug/ml), C.neoformans 316 (MIC >500 ug/ml), and A.fumigatus X 807219 (MIC>500 ug/ml) ( van't Hof et al., 2000 ). Also active against
Evidence 45 Activity

Activity

MIC
Antiviral
>500 µg/mL

Target

A.fumigatus X 807219

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

9 (MIC >500 ug/ml), C.krusei 355 (MIC >500 ug/ml), C.neoformans 316 (MIC >500 ug/ml), and A.fumigatus X 807219 (MIC>500 ug/ml) ( van't Hof et al., 2000 ). Also active against P. falciparum (IC50 ~100 uM) (see ref AP4
Evidence 46 Activity

Activity

Cell-penetrating Peptides

Target

Monomac6 Human Monocytes

Source & Reference

CPPsite3.0
CPPsite3

Other

Source Activity Label Source Definition
Cell-penetrating Peptides
CPPsite3.0 experimentally validated cell-penetrating peptide annotation.
Natural residues Linear L Cationic
Protein derived
No difference in cellular uptake slightly between Cf-labelled and non-labelled
In vitro
CCSCSSCCSCCCC
Evidence 47 Activity

Activity

50% Hemolysis
Toxicity
19±1.0 µM
Hemolytic Cytotoxic
50% Hemolysis | 19±1.0 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
A critical comparison of the hemolytic and fungicidal activities of cationic antimicrobial peptides | FEBS Lett | 1999
Evidence 48 Activity

Activity

50% Hemolysis
Toxicity
17±1.0 µM
Hemolytic Cytotoxic
50% Hemolysis | 17±1.0 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
A critical comparison of the hemolytic and fungicidal activities of cationic antimicrobial peptides | FEBS Lett | 1999
Evidence 49 Activity

Activity

50% Hemolysis
Toxicity
8.0±0.1 µM
Hemolytic Cytotoxic
50% Hemolysis | 8.0±0.1 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
A critical comparison of the hemolytic and fungicidal activities of cationic antimicrobial peptides | FEBS Lett | 1999
Evidence 50 Activity

Activity

50% Hemolysis
Toxicity
7.2±3.4 µM
Hemolytic Cytotoxic
50% Hemolysis | 7.2±3.4 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
A critical comparison of the hemolytic and fungicidal activities of cationic antimicrobial peptides | FEBS Lett | 1999
Evidence 51 Activity

Activity

0% Hemolysis
Toxicity
25 µg/mL
Hemolytic Cytotoxic
0% Hemolysis | 25 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
All-D-magainin: chirality, antimicrobial activity and proteolytic resistance | FEBS Lett | 1990
Evidence 52 Activity

Activity

1% Hemolysis
Toxicity
80 µg/mL
Hemolytic Cytotoxic
1% Hemolysis | 80 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
All-D-magainin: chirality, antimicrobial activity and proteolytic resistance | FEBS Lett | 1990
Evidence 53 Activity

Activity

2% Hemolysis
Toxicity
200 µg/mL
Hemolytic Cytotoxic
2% Hemolysis | 200 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
All-D-magainin: chirality, antimicrobial activity and proteolytic resistance | FEBS Lett | 1990
Evidence 54 Activity

Activity

50% Hemolysis
Toxicity
>81 µM
Hemolytic Cytotoxic
50% Hemolysis | >81 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
A critical comparison of the hemolytic and fungicidal activities of cationic antimicrobial peptides | FEBS Lett | 1999
Evidence 55 Activity

Activity

50% Cell death
Toxicity
>500 µM
Cytotoxic
50% Cell death | >500 | µM | target cell: Mouse fibroblasts NIH 3T3

Target

Mouse fibroblasts NIH 3T3

Source & Reference

NA
DBAASP
Antimicrobial peptide GW-H1-induced apoptosis of human gastric cancer AGS cell line is enhanced by suppression of autophagy. | Mol Cell Biochem | 2015
Evidence 56 Activity

Activity

Toxicity
Hemolytic Cytotoxic
- | NA | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Peptoid-Substituted Hybrid Antimicrobial Peptide Derived from Papiliocin and Magainin 2 with Enhanced Bacterial Selectivity and Anti-inflammatory Activity. | Biochemistry | 2015
Evidence 57 Activity

Activity

50% Hemolysis
Toxicity
>1000 µM
Hemolytic Cytotoxic
50% Hemolysis | >1000 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Position-dependent hydrophobicity of the antimicrobial magainin peptide affects the mode of peptide-lipid interactions and selective toxicity. | Biochemistry | 2002
Evidence 58 Activity

Activity

50% Hemolysis
Toxicity
>256 µg/mL
Hemolytic Cytotoxic
50% Hemolysis | >256 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
The zebrafish embryo as a tool for screening and characterizing pleurocidin host-defense peptides as anti-cancer agents. | Dis Model Mech | 2011
Evidence 59 Activity

Activity

30% Hemolysis
Toxicity
150 µM
Hemolytic Cytotoxic
30% Hemolysis | 150 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Peptide hydrophobicity controls the activity and selectivity of magainin 2 amide in interaction with membranes. | Biochemistry | 1997
Evidence 60 Activity

Activity

50% Cell death
Toxicity
236 µM
Cytotoxic
50% Cell death | 236 | µM | target cell: Mouse fibroblasts NIH 3T3

Target

Mouse fibroblasts NIH 3T3

Source & Reference

NA
DBAASP
Antimicrobial peptide GW-H1-induced apoptosis of human gastric cancer AGS cell line is enhanced by suppression of autophagy. | Mol Cell Biochem | 2015
Evidence 61 Activity

Activity

50% Hemolysis
Toxicity
479.5±42.9 µM
Hemolytic Cytotoxic
50% Hemolysis | 479.5±42.9 | µM | target cell: Sheep erythrocytes

Target

Sheep erythrocytes

Source & Reference

NA
DBAASP
A Rapid and Quantitative Flow Cytometry Method for the Analysis of Membrane Disruptive Antimicrobial Activity. | PLoS One | 2016
Evidence 62 Activity

Activity

IC50
Toxicity
132±23.8 µM
Cytotoxic
IC50 | 132±23.8 | µM | target cell: Human PBMC

Target

Human PBMC

Source & Reference

NA
DBAASP
Comparative analysis of internalisation, haemolytic, cytotoxic and antibacterial effect of membrane-active cationic peptides: aspects of experimental setup. | Amino Acids | 2017
Evidence 63 Activity

Activity

50% Hemolysis
Toxicity
>300 µM
Hemolytic Cytotoxic
50% Hemolysis | >300 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Comparative analysis of internalisation, haemolytic, cytotoxic and antibacterial effect of membrane-active cationic peptides: aspects of experimental setup. | Amino Acids | 2017
Evidence 64 Activity

Activity

0% Hemolysis
Toxicity
50 µM
Hemolytic Cytotoxic
0% Hemolysis | 50 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Inducing toxicity by introducing a leucine-zipper-like motif in frog antimicrobial peptide, magainin 2. | Biochem J | 2011
Evidence 65 Activity

Activity

25% Cell death
Toxicity
100 µM
Cytotoxic
25% Cell death | 100 | µM | target cell: Chinese hamster ovary cells CHO-K1

Target

Chinese hamster ovary cells CHO-K1

Source & Reference

NA
DBAASP
Inducing toxicity by introducing a leucine-zipper-like motif in frog antimicrobial peptide, magainin 2. | Biochem J | 2011
Evidence 66 Activity

Activity

50% Hemolysis
Toxicity
>100 µM
Hemolytic Cytotoxic
50% Hemolysis | >100 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Development of Antimicrobial Stapled Peptides Based on Magainin 2 Sequence. | Molecules | 2021
Evidence 67 Activity

Activity

0% Hemolysis
Toxicity
64 µM
Hemolytic Cytotoxic
0% Hemolysis | 64 | µM | target cell: Mouse erythrocytes

Target

Mouse erythrocytes

Source & Reference

NA
DBAASP
Antibacterial and Antibiofilm Activity and Mode of Action of Magainin 2 against Drug-Resistant Acinetobacter baumannii. | Int J Mol Sci | 2018
Evidence 68 Activity

Activity

Toxicity
Cytotoxic
NA | target cell: Human keratinocytes HaCat

Target

Human keratinocytes HaCat

Source & Reference

NA
DBAASP
Antibacterial and Antibiofilm Activity and Mode of Action of Magainin 2 against Drug-Resistant Acinetobacter baumannii. | Int J Mol Sci | 2018
Evidence 69 Hemolysis

Source & Reference

APD_complete HemoPI PD_Hemolysis
APD_complete PD_Hemolysis

Other

Source Activity Label Source Definition
Hemolysis
APD_complete APD-derived hemolytic peptide annotation.
Additional Detail Fields 1 fields
CCSCSSCCSCCCC